Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Inventory (2016 - 2026)

Dexcom has reported Inventory over the past 17 years, most recently at $693.6 million for Q1 2026.

  • Quarterly Inventory rose 28.87% to $693.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $693.6 million through Mar 2026, up 28.87% year-over-year, with the annual reading at $629.1 million for FY2025, 15.94% up from the prior year.
  • Inventory was $693.6 million for Q1 2026 at Dexcom, up from $629.1 million in the prior quarter.
  • Over five years, Inventory peaked at $693.6 million in Q1 2026 and troughed at $306.7 million in Q4 2022.
  • The 5-year median for Inventory is $542.6 million (2024), against an average of $498.2 million.
  • Year-over-year, Inventory decreased 14.16% in 2022 and then soared 82.46% in 2023.
  • A 5-year view of Inventory shows it stood at $306.7 million in 2022, then surged by 82.46% to $559.6 million in 2023, then fell by 3.04% to $542.6 million in 2024, then increased by 15.94% to $629.1 million in 2025, then rose by 10.25% to $693.6 million in 2026.
  • Per Business Quant, the three most recent readings for DXCM's Inventory are $693.6 million (Q1 2026), $629.1 million (Q4 2025), and $604.1 million (Q3 2025).